Pharmaceutical Construction

Feature Project

Noven Pharmaceuticals

Project Details

We understand the nuances and details that deliver successful projects in the life sciences industry.

The pharmaceutical industry continuously encounters challenges to discover, produce, and manufacture products to improve the overall health and well-being of the public. Each step in this progression is governed and scrutinized by agencies and regulatory requirements that will ultimately provide or deny product approval and dispensation. Accordingly, pharmaceutical facilities must be constructed with care and precision at the outset of the project.

During our many years of experience, our staff have gained an intimate understanding of the laws and regulations that accompany the construction of pharmaceutical facilities and environments in today’s life sciences industry. Our professionals provide services on programs and projects that involve clean rooms; laboratories; secondary manufacturing, packaging, and launch facilities; biological areas; etc. at a level of detail that corresponds to achieving owner-stated visions and goals by precise coordination of project schedules and tasks. We leave no project detail unattended when working with owners and stakeholders who are vested in providing these sensitive and complex environments.

Construction & Project Management Challenges

In this competitive landscape, flexibility and speed to market are just a few of the challenges we can help you overcome. Learn how PMA has helped deliver pharmaceutical projects.

GENERAL PHARMACEUTICAL INDUSTRY

PMA was engaged prior to project funding to provide third-party estimate reviews for all major capital projects in the United States, Puerto Rico, and in Mexico; project costs ranged between $5 million and $150 million. Facility construction types included research and QA/QC laboratories, chemical production, secondary manufacturing and packaging, and biological. Typical reviews included analyses of both high-level indicators as well as detailed metrics (e.g., hours/lf of pipe).

BIOPHARMACEUTICAL

PMA provided schedule and risk analysis assistance on a $250 million bio-pharma production facility project. To enable the project to develop a systems turnover-based schedule and focus for engineering and construction, PMA assisted with early development of the schedule for all qualification and process validation activities. Once the integrated schedule was complete, PMA performed schedule risk analyses, including a Monte Carlo simulation, to reflect the likelihood of the construction project achieving desired milestones.

PHARMACEUTICAL & BIOTECH LABORATORIES

PMA was retained to analyze and determine the merits of more than ten claims, ranging in value from $15,000 to $10.9 million, submitted by construction services contractors on a new $600 million pharmaceutical laboratory and manufacturing facility. Claims involved work done by multiple prime contractors, including piping, instrumentation, electrical, concrete, HVAC, and mechanical. This project is comprised of a laboratory building, pilot plant, administrative building, visitor center, warehouse, energy center, wastewater treatment plant, and several other buildings and associated infrastructure.

PRIMARY CHEMICAL

The project entailed facility design and construction of a new production unit within an existing launch manufacturing facility. Total cost for the project was approximately $40 million with a total schedule of 22 months from the beginning of conceptual design through start-up of the facility. PMA provided project management controls and cost estimating services that involved the following:

  • Ensuring the construction project had the correct cost and schedule controls in place early in the project
  • Ensuring early cost estimates and schedules were well prepared, unbiased, complete, and comprehensive

SECONDARY MANUFACTURING

Per the request of senior management, PMA was asked to provide an independent review of two major secondary manufacturing projects, focusing on risks to the construction management project, validity of the latest cost forecast/estimate, and the schedule-to-complete.

Each review involved a detailed investigation at the project site and included interviews with key project team personnel and a review of relevant project documents. The PMA review team, focusing on areas of concern, performed detailed analyses of issues and risks to help develop an accurate status of the project.

Detailed analyses included:

  • Review of the cost forecast for completeness, accuracy, up-to-date information, and methodology of projections
  • Review of the schedule to ensure it was representing the project status, was accurate for predicting path forward, and that sound practices were being followed
  • Review of change order status and system
  • Assessment of contingency
  • Assessment of risks, possible impacts to project cost and schedule, and potential mitigation steps
  • Review of the organizational structure, roles, and responsibilities
Johnson & Johnson, Worldwide Engineering Department

Various locations, FL

Shire Manufacturing Plant & Human Genetic Therapies Headquarters

Lexington, MA

Bristol-Myers Squibb Biologics Facility

Devens, MA

Noven Pharmaceuticals

Miami, FL